Invited Speakers - more to come!

The University of Auckland

Read More

Ian Reid is an endocrinologist and Distinguished Professor at the University of Auckland.  His research interests include calcium metabolism, vitamin D, osteoporosis and Paget’s disease. He has written extensively about the safety and efficacy of calcium supplements, how to define vitamin D deficiency, and has been involved in development of most new osteoporosis treatments in the last 30 years, particularly the bisphosphonates. He is a past-president of the International Bone and Mineral Society (IBMS), and recipient of research awards from the Australian & New Zealand Bone & Mineral Society, the European Calcified Tissue Society, the American Society of Bone and Mineral Research, and the New Zealand Prime Minister’s Science Prize. 

Royal Brisbane & Women's Hosptial

Read More

Dr Helen Barrett is an Endocrinologist and Obstetric Medicine Physician. She is Director of Obstetric Medicine at The Royal Brisbane and Women's Hosptial (RBWH) and a Senior Staff Specialist in Obstetric Medicine and Endocrinology. She is a conjoint Associate Professor at UNSW Medicine and an Honorary Senior Research Fellow at Mater Research Institute - The University of Queensland. Helen is also a Past President of the Society of Obstetric Medicine Australia New Zealand (2020-2022). Helen is a clinician researcher and completed her PhD examining the role of lipids in diabetes in pregnancy in 2014 at the University of Queensland. Helen has a particular research interest in maternal and placental metabolism in high-risk pregnancy, relating to diabetes and pre-eclampsia.

Rhythm Endocrinology and Diabetes

Read More

Associate Professor Warrick Inder is an endocrinologist at Rhythm Endocrinology and Diabetes in Brisbane. He graduated from the University of Otago, New Zealand in 1988 and completed his MD examining the effects of opioid peptides on ACTH secretion. He then undertook a 2 year post-doctoral fellowship in the Neuroendocrine Unit of the Massachusetts General Hospital, Boston USA researching pituitary adenomas, before returning as a consultant Endocrinologist at Christchurch Hospital, NZ. In 2001, he moved to Australia, working for 10 years at St Vincent’s Hospital, then relocated to Brisbane in 2011, where he worked as an eminent staff specialist at Princess Alexandra Hospital until 2025. He is an associate professor with the University of Queensland, with broad research interests including pituitary, adrenal and reproductive endocrinology. He is an ESA past-president and was presented with an ESA Outstanding Clinical Practitioner Award in 2021. In 2022 he was conferred as an ESA honorary life member.

Westmead Hospital

Read More

Shejil is an Endocrinology staff specialist at Westmead Hospital and is undergoing a PhD at the University of Sydney based at Royal North Shore and Westmead Hospital, Sydney. He is running the ROLEX-DUO clinical trial combining romosozumab with high intensity resistance exercise in postmenopausal osteoporosis. He has academic interests in sequential and combination osteoanabolic treatments and denosumab rebound. He is also passionate about promoting career and professional development for early career clinicians and scientists through his current roles as Co-Chair of the ANZBMS ECIC, Co-Convenor of the ESA Clinical Weekend and host of the ESA Hormone Hotseat podcast.

Hudson Institute of Medical Research

Read More

Frances Milat is an endocrinologist and researcher with expertise in osteoporosis, metabolic bone disorders and women’s health. She is Head of the Metabolic Bone Research Group, Hudson Institute, where she leads a research program focused on osteoporosis in young adults and bone health in chronic disease. She is also the Head of the Metabolic Bone Service at Monash Health. Fran has been the recipient of the Endocrine Society of Australia Outstanding Clinical Practitioner Award, the Australian and New Zealand Bone and Mineral Society Kaye Ibbertson Award and the ESA Mid-Career Award.  Her PhD students have won multiple international and national awards for excellence. A/Prof Milat has extensive experience in clinical guideline development and serves on multiple national and international committees to advocate and foster excellence in endocrine practice, research and education. Fran also has a keen interest in the medical humanities.

St Vincent’s Hospital

Read more

Dr Jennifer Snaith is clinical researcher and Staff Specialist endocrinologist who leads the Diabetes in Youth service at St Vincent’s Hospital, Sydney. Her research interest is the intersection between type 1 diabetes, metabolic and cardiovascular health, and the role of adjunctive therapies in type 1 diabetes. She was awarded the UNSW Dean’s Award for her PhD, a study of the effect of metformin on muscle and liver insulin resistance in type 1 diabetes, assessed using hyperinsulinaemic-euglycaemic clamps. She conducts adjunctive therapies clinical trials in type 1 diabetes through the Garvan Institute of Medical Research and the Victor Chang Cardiac Research Institute. Active or completed trials include the INTIMET study (metformin), RESET1 (semaglutide), TIRTLE1 (tirzepatide) and TIRTLE2 (tirzepatide). Jen’s post-doctoral work is a supported by Breakthrough T1D Australia.

Royal Melbourne Hospital

Read More

Dr Angeline Shen is dual trained in both Endocrinology and General medicine. She is an Endocrinology staff specialist at the Royal Melbourne hospital, Sunshine Hospital and Victorian comprehensive cancer centre (VCCC). She completed her PhD studies at the University of Melbourne, examining the long-term clinical outcomes of patients with functional pituitary tumours as well as the molecular genetic profiles of these rare tumours. In 2024, she was awarded the young investigator awards at ANZPA. In addition to Endocrinology, she is passionate about teaching and is the deputy director of Basic Physician training program at The Royal Melbourne Hospital.

Frazer Institute, University of Queensland

Read More

Michael is currently Director of the Hypertension Units and of the Endocrine Hypertension Research Centre within the University of Queensland Frazer Institute at Greenslopes and Princess Alexandra Hospitals in Brisbane. He has over 30 years clinical research experience in pathogenesis and management of hypertension and especially of endocrine varieties including primary aldosteronism, renovascular hypertension, pheochromocytoma and familial hyperkalemic hypertension. Working with mentor Richard Gordon, he helped to demonstrate that primary aldosteronism is at least 10 times more common than previously thought, and is the commonest specifically treatable and potentially curable form of hypertension. Subsequent studies have involved determining genetic bases for primary aldosteronism, examining non-blood pressure dependent effects of aldosterone excess, improving methods of detection, diagnostic workup and management of primary aldosteronism, exploring the pathogenesis and genetics of other salt sensitive forms of hypertension (including familial hyperkalemic hypertension) and investigating how dietary potassium lowers blood pressure.

Royal Brisbane & Women’s Hospital

Read More

Prof Pattison underwent dual training in nuclear medicine and endocrinology and is the Director of Department of Nuclear Medicine, PET & Theranostics at Royal Brisbane & Women’s Hospital. He holds an academic appointment at the University of Queensland and his major research focus is on theranostics for neuroendocrine tumours, thyroid cancer and prostate cancer. He has been a chief investigator on numerous competitive grants (>$20m) for theranostics, including neuroendocrine tumours (STOPNET trial), redifferentiation of radioactive iodine refractory thyroid cancer (I-FIRST trial) and prostate cancer. He introduced Fluorocholine PET/CT imaging to Brisbane and is supervising a PhD student conducting an RCT comparison to conventional imaging (4DCT & sestamibi).

Internationally, he sits on the Thyroid and Head and Neck Cancer (THANC) Foundation Medical Advisory Board for Thyroid International Recommendations Online. Nationally, he is a Board Director for the Australasian Association of Nuclear Medicine Specialists (AANMS), Chairs the Australian Nuclear Science and Technology Organisation (ANSTO) Lutetium Working Group and is co-author of the Neuroendocrine Tumour Imaging section of the current Clinical Oncology Society of Australia (COSA) Guidelines. He was convenor of the inaugral AANMS Theranostics Course in 2022 and 2024.